Skip to main content

Advertisement

Table 1 Characteristics of the groups.

From: Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study

  ALL PATIENTS  
PARAMETER Group with AF n = 25 Group without AF n = 44 p
Age 57 ± 10.26 59 ± 13 ns
-female -male 3 22 7 37 0.04
diabetes mellitus 7 (28%) 9 (20%) ns
cigarette smoking 4 (16%) 4 (9%) ns
BMI 28 ± 4 25 ± 3 ns
NYHA class median 2 3 ns
Heart failure assessment
dyspnoea (1)* 13 (52%) 18 (43%) ns
oedema (1) 6 (25%) 4 (9%) ns
pulmonary hemostasis1 5 (21%) 3 (7%) ns
6-MWT (1) 405 ± 71 381.9 ± 96 ns
6-MWT (2)* 434 ± 109 419.1 ± 114 ns
HR mean 78 77 ns
Pharmacological treatment
atorvastatin 17 (68%) 27 (61%) ns
carvedilol 23 (92%) 38 (86%) ns
ACE-I 23 (92%) 42 (95%) ns
ARB 2 (8%) 3 (7%) ns
spironolactone/eplerenone 22 (88%) 40 (93%) ns
diuretics 22 (88%) 42 (95%) ns
aspirin 9 (36%) 20 (45%) ns
digoxin 14 (56%) 4 (9%) 0.001
warfarin 24 (96%) 3 (6.8%) 0.001
insulin 1 (4%) 3 (7%) ns
oral hypoglycaemics 3 (12%) 4 (9%) ns
Echocardiographic characteristics
LA enlargement [cm] 22 (88%) 37 (84%) ns
LVEDD [cm] 7.3 ± 0.9 7.0 ± 0.8 ns
LVESD [cm] 6 ± 2 5.7 ± 1 ns
diastolic dysfunction 2 (8%) 6 (13.6%) ns
LVEDV[cm] 240.24 ± 99 200.55 ± 57 ns
LVESV [cm] 175.11 ± 86 147.33 ± 56.58 ns
EF (%) 30% 29% ns
mitral incompetence I II III 11 (44%) 5 (20%) 3 (12%) 15 (34%) 16 (36%) 10 (24%) ns
pulmonary hypertension 7 (28%) 13 (30%) ns
Biochemical parameters
TNF-α (1) [pg/ml] 20.2 ± 28 16.5 ± 17 ns
IL-6 (1) [pg/ml] 20.6 ± 20 13.8 ± 10 ns
IL-10 (1) [pg/ml] 14.2 ± 12 24.9 ± 41 ns
NT-proBNP (1) [pg/ml] 2669.4 ± 2192 1540.7 ± 1513 0.02
  1. * (1) variables assessed after inclusion, (2) variables assessed after 2 months
  2. ABBREVIATIONS: BMI - body mass index; HR - heart rate; AF - atrial fibrillation; NYHA - New York Heart Association; 6-MWT - 6-minute walk test, ACE-I - angiotensin-converting enzyme inhibitor; ARB - angiotensin II receptor antagonist; LA - left atrium; LVEDD - left ventricular end-diastolic diameter; LVEF - left ventricular ejection fraction; LVESD - left ventricular end-systolic diameter; LVEDV - left ventricular end-diastolic volume; LVESV - left ventricular end-systolic volume, TNF-a - tumour necrosis factor-alpha; IL - interleukin; NT-proBNP - N-terminal pro-brain natriuretic peptide.